Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $973.13 Consensus Price Target from Analysts
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-five analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, sixteen have issued a buy recommendation and […]
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-five analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, sixteen have issued a buy recommendation and […]
